Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
Open Access
- 1 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Dermatology and Therapy
- Vol. 10 (1), 133-150
- https://doi.org/10.1007/s13555-019-00340-3
Abstract
Introduction Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. Methods Integrated safety data were analyzed from 13 ixekizumab clinical studies. Rates of treatment-emergent adverse events (TEAEs), serious AEs (SAEs) and AEs of special interest were analyzed for the 12-week induction period in the combined pivotal studies, and for all pooled studies by year(s) of therapy and overall, reported as exposure-adjusted incidence rates (IRs) per 100 patient-years (p-y) and/or frequencies. Results Total ixekizumab exposure was 17,003.4 p-y (N = 5898); 2749 patients had >= 4 years of exposure. When compared across years of exposure, rates for AEs remained largely stable or declined, including TEAEs leading to discontinuation (3.8/100 p-y in year 1, declining to 2.0/100 p-y in year 5); SAEs (range 6.2-7.0/100 p-y); serious infections (range 1.3-1.7/100 p-y); nonmelanoma skin cancer (ranging from 0.5/100 p-y in year 1 to 0.2/100 p-y in years 4-5); other malignancies (range 0.4-0.6/100 p-y); inflammatory bowel disease including ulcerative colitis and Crohn's disease (IR 0.2/100 p-y); and major adverse cardiovascular events (MACE) (range 0.3-0.7/100 p-y). Candidiasis was reported in 327 patients (IR 1.9/100 p-y), with the majority identified as mucocutaneous. The rate of injection site reactions was 15.5/100 p-y during year 1 and 2.0-2.3/100 p-y by years 3-5. Conclusions The decrease in rates of TEAEs and the stable rates of SAEs, other malignancies and MACE during up to 5 years of ixekizumab dosing are consistent with previous reports describing a favorable safety profile of ixekizumab following shorter durations of exposure. Funding Eli Lilly and Company.Keywords
Funding Information
- Eli Lilly and Company
This publication has 47 references indexed in Scilit:
- Immunity to infection in IL‐17‐deficient mice and humansEuropean Journal of Immunology, 2012
- Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular DiseaseThe American Journal of Cardiology, 2011
- Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular EventsAmerican Journal Of Medicine, 2011
- IL-17 signaling in host defense against Candida albicansImmunologic Research, 2011
- Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 ImmunityScience, 2011
- Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature reviewRheumatology, 2010
- Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.British Journal of Dermatology, 2010
- Precarious Balance: Th17 Cells in Host DefenseInfection and Immunity, 2010
- Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research DatabaseEuropean Heart Journal, 2009
- A protective function for interleukin 17A in T cell–mediated intestinal inflammationNature Immunology, 2009